Literature DB >> 18256920

CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG.

David A Clark1, Karrie Wong, Daljeet Banwatt, Ziqhi Chen, Jian Liu, Lydia Lee, Reginald M Gorczynski, Morris A Blajchman.   

Abstract

PROBLEM: Intravenous immunoglobulin (IVIG) has been used to suppress autoimmune and inflammatory disorders by a variety of mechanisms. Recently, the CD200 tolerance-promoting signal has been found to play a role in IVIG suppression of blood natural killer (NK) cells. Further, different types of IVIG have been reported to differ in this activity, and that has been related to efficacy (and inefficacy) of treatment of women with pregnancy failure. CD200 acts by binding to CD200 receptors (C200R). The objective of this study was to determine if CD200-dependent NK suppression by IVIG involved direct binding of IVIG-associated CD200 molecules to CD200R on NK cells. METHOD OF STUDY: Peripheral Blood Lymphocytes isolated from human blood were used as a source of NK cells to lyse Cr(51)-labelled K562 target cells in vitro in 18 and 4 h assays, and three different types of IVIG were tested for suppressive activity in the presence or absence of specific monoclonal anti-huCD200. In some experiments, CD56(+) NK cells were purified using anti-CD56 magnetic beads. Western blotting of IVIG using a specific anti-huCD200 antibody was done. Enzyme-Linked ImmunoSorbent Assays were used to measure cytokine production in NK assays.
RESULTS: Different IVIGs showed significant differences in potency in suppressing NK cytolytic activity in vitro (mg/ml for 60% suppression, Gammagard 4.1, Gamunex 14.1, Gamimmune 20.2). For CD200-dependent suppression, Gammagard was twice as potent as Gamimmune, but equivalent to Gamunex. The presence of suppression in 4 hour assays indicated stimulation of cytokine synthesis was unlikely to explain CD200-dependent suppression. Purification of NK cells led to loss of the CD200-dependent component. Western blotting confirmed that material reactive with anti-CD200 antibody was present in Immunoglobulin G (IgG) preparations, and at a lower level in human serum that contains IgG.
CONCLUSIONS: IVIGs are not all equipotent in suppressing NK cell cytolytic activity. CD200 associated with IVIG is an important component of suppression. CD200-dependent suppression appears to be mediated by a non-NK population that then acts on NK cells by direct contact rather than indirectly through release of immunosuppressive cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256920      PMCID: PMC2582113          DOI: 10.1007/s10815-008-9202-9

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  15 in total

1.  Loss of surface CD200 on stored allogeneic leukocytes may impair anti-abortive effect in vivo.

Authors:  David A Clark; Gerard Chaouat
Journal:  Am J Reprod Immunol       Date:  2005-01       Impact factor: 3.886

Review 2.  Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.

Authors:  Kamran Darabi; Omar Abdel-Wahab; Walter H Dzik
Journal:  Transfusion       Date:  2006-05       Impact factor: 3.157

3.  Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R.

Authors:  Reginald M Gorczynski; Lydia Lee; Ivo Boudakov
Journal:  Transplantation       Date:  2005-05-15       Impact factor: 4.939

Review 4.  Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF).

Authors:  David A Clark; Carolyn B Coulam; Raphael B Stricker
Journal:  J Assist Reprod Genet       Date:  2006-01-19       Impact factor: 3.412

5.  Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells.

Authors:  Michael Stassen; Sabine Fondel; Tobias Bopp; Christoph Richter; Christian Müller; Jan Kubach; Christian Becker; Jürgen Knop; Alexander H Enk; Steffen Schmitt; Edgar Schmitt; Helmut Jonuleit
Journal:  Eur J Immunol       Date:  2004-05       Impact factor: 5.532

6.  Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface.

Authors:  Reginald M Gorczynski; Zhiqi Chen; David A Clark; Yu Kai; Lydia Lee; Joseph Nachman; Simon Wong; Philip Marsden
Journal:  Am J Reprod Immunol       Date:  2004-08       Impact factor: 3.886

7.  Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Authors:  Gavin J Wright; Holly Cherwinski; Mildred Foster-Cuevas; Gary Brooke; Michael J Puklavec; Mike Bigler; Yaoli Song; Maria Jenmalm; Dan Gorman; Terri McClanahan; Man-Ru Liu; Marion H Brown; Jonathon D Sedgwick; Joseph H Phillips; A Neil Barclay
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

8.  Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.

Authors:  Itay Shalev; Hao Liu; Cheryl Koscik; Agata Bartczak; Mojib Javadi; Kit Man Wong; Asif Maknojia; Wei He; Ming Feng Liu; Jun Diao; Erin Winter; Justin Manuel; Doug McCarthy; Mark Cattral; Jennifer Gommerman; David A Clark; M James Phillips; Reginald R Gorczynski; Li Zhang; Greg Downey; David Grant; Myron I Cybulsky; Gary Levy
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

9.  Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion.

Authors:  J E Ruiz; J Y Kwak; L Baum; A Gilman-Sachs; K D Beaman; Y B Kim; A E Beer
Journal:  Am J Reprod Immunol       Date:  1996-04       Impact factor: 3.886

10.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  7 in total

Review 1.  NK cells, autoantibodies, and immunologic infertility: a complex interplay.

Authors:  Caterina De Carolis; Carlo Perricone; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

2.  A high dose intravenous immunoglobulin therapy for women with four or more recurrent spontaneous abortions.

Authors:  Hideto Yamada; Masamitsu Takeda; Yoko Maezawa; Yasuhiko Ebina; Ryoichi Hazama; Kenji Tanimura; Yukio Wakui; Shigeki Shimada
Journal:  ISRN Obstet Gynecol       Date:  2012-09-11

Review 3.  Intravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines.

Authors:  Nayoung Sung; Ae Ra Han; Chan Woo Park; Dong Wook Park; Joon Cheol Park; Na Young Kim; Kyung Sil Lim; Ji Eun Shin; Chang Woo Joo; Seung Eun Lee; Jae Won Kim; Sung Ki Lee
Journal:  Clin Exp Reprod Med       Date:  2017-03-31

4.  Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key Similarities and Differences: Potential Implications for Their Applications in Regenerative Medicine.

Authors:  Andrea Papait; Elsa Vertua; Marta Magatti; Sabrina Ceccariglia; Silvia De Munari; Antonietta Rosa Silini; Michal Sheleg; Racheli Ofir; Ornella Parolini
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600

Review 5.  CD200:CD200R Interactions and Their Importance in Immunoregulation.

Authors:  Katarzyna Kotwica-Mojzych; Barbara Jodłowska-Jędrych; Mariusz Mojzych
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 6.  Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.

Authors:  Wen-Xuan Li; Xiang-Hong Xu; Li-Ping Jin
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

7.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.